The International Conference on Malignant Lymphoma (ICML), which will be held June 18-22, 2019 in the Palazzo dei Congressi, Lugano, Switzerland and is organized by the Institute of Oncology Research (IOR) in cooperation with the American Association for Cancer Research (AACR), is one of the must-attend events for the scientific community involved in the study and treatment of lymphoid neoplasms. During the meeting, expect presentation of the most recent data—basic, translational and clinical—on lymphoma.
In addition to the latest scientific data, the meeting offers the more 3,500 expected attendees from over 74 countries the opportunity to discuss the findings with peers, including hematologists, clinical oncologists, radiation oncologists, pediatricians, pathologists, and leading researchers from all over the world.
The editors of ADC Review, Journal Antibody-drug Conjugates have created the following guide to all presentations related to ADCs for the upcoming 15th ICML.
|wdt_ID||Type||Title||Abstract #||Date / Time||Location||Presenter|
|1||Oral Presentation||Polarix: A Phase 3 Study of Polatuzumab Vedotin (Pola) Plus R-CHP Versus R-CHOP In Patients (PTS) With Untreated DLBCL||OT02||Wednesday, June 19, 5:15 p.m. CEST Aula Magna (USI Università)||Hervé Tilly; Centre Henri Becquerel, University of Rouen, Rouen, France|
|2||Oral Presentation||Safety and Response after 2 Cycles of Brentuximab Vedotin Substituting Vincristine in the OEPA/COPDAC Regimen for High Risk Pediatric Hodgkin Lymphoma (HL)||#025||Wednesday, June 19, 5:25 p.m. CEST||Cinema Corso||Jamie Flerlage, MD, MS, Oncology Department, St. Jude Children's Research Hospital Memphis, TN|
|3||Oral Presentation||Response-Adapted Treatment with Nivolumab and Brentuximab Vedotin in Young Patients with Relapsed/Refractory Classical Hodgkin Lymphoma: Checkmate 744 Subgroup Analyses||#026||Wednesday, June 19, 5:35 p.m. CEST||Cinema Corso||Kara Kelly, MD, Professor of Oncology, Chair, Department of Pediatric Oncology | John R. Oishei Children’s Hospital of Buffalo, NY|
|4||Oral Presentation||Analysis of Efficacy and Safety of Loncastuximab Tesirine (ADCT-402) by Demographic and Clinical Characteristics in Relapsed/Refractory Diffuse Large B-Cell Lymphoma||#054||Thursday, June 20, 16:25 CEST||Room A, Cinema Corso Auditorium and Aula Magna||John Radford MD, FRCP, Department of Medical Oncology, The University of Manchester and The Christie NHS Foundation Trust, Manchester, UK|
|5||Oral Presentation||Analysis of Clinical Determinants Driving Safety and Efficacy of Camidanlumab Tesirine (ADCT-301, Cami) in Relapsed/Refractory (R/R) Classical Hodgkin Lymphoma (cHL)||#055||Thursday, June 20, 16:40 CEST||Room A, Cinema Corso Auditorium and Aula Magna||Graham Collins, MB, BS, DPhil, Department of Clinical Haematology, Oxford University Hospitals, NHS Foundation Trust, Oxford, UK|
|6||Oral Presentation||Extended Follow-up a Phase 1 Study of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Research Group (E4412: Arms A-I)||#077||Thursday, June 20, 5:45 p.m. CEST||Cinema Corso||Catherine (Magid) Diefenbach, MD, NYU Langone Clinical Cancer Center, New York, NY|
|7||Oral Presentation||The Antibody-Drug Conjugate (ADC) Loncastuximab Tesirine (ADCT-402) Targeting CD19 Shows Strong In Vitro Anti-Lymphoma Activity Both as Single Agents and In Combination||#084||Thursday, June 20, 17:55 CEST||Auditorium (USI Universitá)||Chiara Tarantelli, PhD, Università della Svizzera italiana, Institute of Oncology Research|
|8||Oral Presentation||Nivolumab Combined with Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-cell Lymphoma: Efficacy and Safety Results from the Phase 2 Checkmate 436 Study||#108||Friday, June 21, 2:15 p.m. CEST||Room B, Palazzo dei Congressi||Pier Luigi Zinzani, MD, PhD, Professor of Hematology, Head of Lymphoma Group, Institute of Hematology, “L. e A. Seràgnoli”, University of Bologna, Bologna, Italy.|
|9||Oral Presentation||Polatuzumab Vedotin (Pola) +Obinutuzumab (G) + Lenalidomide (LEN) in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL): Phase IB/II Interim Analysis||#126||Saturday, June 22, 9:00 a.m. CEST||Room A + B, Palazzo dei Congressi||Andrew McMillan, MD, Nottingham University Hospitals NHS Trust|
|10||Poster Presentation||Response to A+CHP by CD30 Expression in the ECHELON-2 Trial||#228||Wednesday-Friday, June 19-21, 12:00-5:00 p.m., 9:00 a.m.-5:00 p.m. and 9:00 a.m.-6:30 p.m. respectively, CEST||Marquee Parco Ciani|